Selexis SA has signed a strategic agreement with Zyngenia Inc. in which Selexis will utilize its SURE Cell Line Development Platform to generate production cell lines for Zyngenia’s lead Zybody therapeutic programs.

“We are excited to support Zyngenia in the rapid advancement of their lead Zybody products,” said Dr. Igor Fisch, chief executive officer and co-founder of Selexis SA. “It’s rare in today’s biotech environment to find a truly innovative antibody platform such as Zyngenia’s, where multiple disease targets can be addressed with a single protein therapy.”

“We recognize the importance of incorporating industry-leading technologies in the development of our products and are pleased to be working with the experts at Selexis,” added David Hilbert, Ph.D., head of R&D at Zyngenia. “Selexis’ technological focus, aggressive development strategies, and commercial flexibility were important factors in our choice of providers in this area.”